Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE009 (AUS) (Dr. Novak)
· consented 2022-06-15
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-24 (study day 455); relationship: N
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-04 (study day 496); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-22 (study day 514); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-27 (study day 611); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-05-24 (study day 698); relationship: N
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-11-07 (study day 865); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.